Objective: To describe diagnostic and therapeutic management of a rare parotid lesion: sclerosing polycystic adenosis.
Patient And Method: We report a case of persistent right intraparotid tumefaction.
Results: A 68-year-old man was referred with a right parotid nodule of 2 years' evolution. Cytology diagnosed pleomorphic adenoma, verified on MRI. Conservative subtotal parotidectomy diagnosed sclerosing polycystic adenosis. Over 1 year's regular follow-up, there were no signs of local recurrence.
Conclusion: Sclerosing polycystic adenosis of the parotid gland is a rare and recently described entity presenting several analogies to the much more frequent cystic mastitis. Although benign and well-delimited, it requires complete exeresis of the parotid, due to a non-negligible risk of recurrence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.anorl.2010.02.005 | DOI Listing |
Virchows Arch
October 2024
Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Folia Neuropathol
August 2024
Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
Histopathology
January 2025
Department of Pathology, The University of Chicago, Chicago, IL, USA.
With the advancement of molecular testing and the routine use of immunohistochemical stains, salivary gland tumours previously categorized as adenoma or adenocarcinoma, not otherwise specified, are being reclassified with distinct diagnoses. Newly recognized benign entities include: sclerosing polycystic adenoma, keratocystoma, intercalated duct hyperplasia and adenoma, and striated duct adenoma. Newly recognized malignant salivary gland tumours include: microsecretory adenocarcinoma, sclerosing microcytic adenocarcinoma, and mucinous adenocarcinoma.
View Article and Find Full Text PDFHead Neck Pathol
June 2024
Department of Pathology, UT Southwestern Medical Center, MC 9073, 5323 Harry Hines Blvd., Dallas, TX, 75390-9073, USA.
Background: Intraductal carcinoma (IDC) of the salivary glands is a confounding entity, our understanding of which continues to evolve. At least four forms have been elucidated based on histomorphology, immunophenotype, and molecular profile: (1) intercalated duct-like, S100/SOX10+ with frequent NCOA4::RET fusions; (2) oncocytic, S100/SOX10+ with TRIM33::RET, NCOA4::RET, and BRAF V600E; (3) apocrine, AR+ with PI3 kinase pathway mutations; and (4) mixed/hybrid intercalated duct-like/apocrine, with S100/SOX10+ and AR+ areas and frequent TRIM27::RET. The revelation that myoepithelial cells harbor the same fusion as luminal cells suggested that fusion-positive cases are not in situ carcinomas as previously believed.
View Article and Find Full Text PDFMol Genet Genomic Med
June 2024
Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!